Inflammation-responsive molecular-gated contact lens for the treatment of corneal neovascularization

Corneal neovascularization (CNV) badly damages the corneal transparency, resulting in visual disturbance and blindness. The frequent administration of glucocorticoid eye drops in clinical increases the possibility of side effects and reduces patient compliance. Considering CNV is often accompanied b...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Journal of controlled release 2023-08, Vol.360, p.818-830
Hauptverfasser: Sun, Rong, Ma, Shuting, Chen, Xi, Deng, Yaxin, Gou, Jingxin, Yin, Tian, He, Haibing, Wang, Yanjiao, Tang, Xing, Zhang, Yu
Format: Artikel
Sprache:eng
Schlagworte:
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
Beschreibung
Zusammenfassung:Corneal neovascularization (CNV) badly damages the corneal transparency, resulting in visual disturbance and blindness. The frequent administration of glucocorticoid eye drops in clinical increases the possibility of side effects and reduces patient compliance. Considering CNV is often accompanied by an increase in ROS production, a ROS-responsive monomer 2-(methylthio)ethyl methacrylate was introduced into the matrix as a “gating switch”. The prepared dexamethasone contact lenses (MCLs@Dex) showed a significant H2O2-responsive release for 168 h. To avoid corneal hypoxia and neovascularization caused by long-term wearing, high‑oxygen-permeability fluorosiloxane materials were incorporated. The oxygen permeability of MCLs@Dex was 4 times that of commercially available hydrogel contact lenses and had ultra-low protein adsorption, which meets the requirements of long-term wearing. In vivo pharmacokinetic studies showed that MCLs@Dex increased the mean residence time by 19.7 times and bioavailability by 2.29 times compared with eye drops, validating the ROS response and sustained release properties. More importantly, MCLs@Dex had satisfactory effects on reducing inflammation and decreasing the related cytokines and oxidative stress levels, and demonstrated significant inhibition of neovascularization, with a suppression rate of 76.53% on the 14th day. This responsive drug delivery system provides a promising new method for the safe and effective treatment of ocular surface diseases. A long-term corneal contact lens with inflammation-responsive molecular-gated drug release, which can self-adaptively release dexamethasone in the high ROS environment, and play a role in enhancing efficacy and reducing toxicity. [Display omitted] •Molecular-gated contact lens for the treatment of corneal neovascularization•Responsive release of dexamethasone at the site of inflammation•High oxygen permeability and good biocompatibility for 7-day continuous wear
ISSN:0168-3659
1873-4995
DOI:10.1016/j.jconrel.2023.07.036